SynCore Biotechnology Co (杏國新藥) is planning an interim analysis of its pancreatic cancer treatment, SB05PC, later this month to determine the drug’s safety and efficacy.
The company is conducting a phase III trial for the drug in Taiwan, the US, France, Hungary, South Korea, Russia and Israel, SynCore general manager Su Muh-hwan (蘇慕寰) told the Taipei Times on Thursday by telephone.
The company aims to use the drug as a second-line treatment in combination with gemcitabine, a chemotherapy medication, for people who do not respond to first-line medicine Folfirinox, a combination of leucovorin, fluorouracil, irinotecan and oxaliplatin.
Participants in the phase III trial are randomly separated into two groups, with one injected with only gemcitabine and the other tested with a combination of gemcitabine and SB05PC, Su said.
As SB05PC is designed to prolong a person’s life, SynCore cannot enter into interim analysis of the drug until half of enrolled participants pass away, he said.
Now that 101 of the 200 participants have died, SynCore can collect data and conduct an interim analysis to evaluate if people survive longer than those who have not taken the drug, he said.
During the phase II trial, participants who took SB05PC and gemcitabine had an average overall survival period of nine months, compared with 7.4 months for those who only received gemcitabine, Su said.
Overall survival is the length of time from the start of treatment to a person’s death, he added.
As for the drug’s progression-free survival (PFS) — the length of time during and after treatment that the disease does not get worse — participants who took SB05PC and gemcitabine had an average PFS period of 4.9 months, compared with 3.5 months for those only taking gemcitabine, he said.
SynCore had planned to enroll 218 participants, but the US Food and Drug Administration has approved adjusting that number based on the outcome of the interim analysis, Su said.
The company plans to end enrollment for the phase III trial by the end of this year and complete the trial by the end of next year on the expectation that participants would survive from seven to nine months, he said.
If everything goes smoothly, SynCore plans to apply to the US regulator for marketing approval of the drug in 2022, he added.
SynCore in February delayed its original plan to begin another phase III trial of SB05PC in China as many patients could not go to hospitals due to a lockdown amid a COVID-19 outbreak.
Su said that the firm plans to delay the clinical trial to August.
Elon Musk’s lieutenants have reached out to chip industry suppliers, including Applied Materials Inc, Tokyo Electron Ltd and Lam Research Corp, for his envisioned Terafab, early steps in an audacious and likely arduous attempt to break into the production of cutting-edge chips. Staff working for the joint venture between Tesla Inc and Space Exploration Technologies Corp (SpaceX) have sought price quotes and delivery times for an array of chipmaking gear, people familiar with the matter said. In past weeks, they’ve contacted makers of photomasks, substrates, etchers, depositors, cleaning devices, testers and other tools, according to the people, who asked not to
Taiwan is attracting a growing number of foreign jobseekers as companies increasingly recruit overseas talent to ease labor shortages and expand global reach, recruitment platform 104 Job Bank (104人力銀行) said yesterday. More than 40,000 foreign nationals searched for jobs in Taiwan through the platform last year, a 28 percent increase from a year earlier, the company said. Malaysians accounted for the largest share of overseas jobseekers at 12.2 percent, followed by Indonesians at 11.9 percent and Vietnamese at 10.8 percent. Indonesian applicants surged more than 50 percent year-on-year, while Vietnamese jobseekers rose by more than 30 percent. Applicants from the
NO SHORTCUTS: Asked about Elon Musk’s Terafab initiative, TSMC CEO C.C. Wei said it takes two to three years to build a fab and another one to two to ramp it up Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) yesterday raised its revenue growth forecast for this year to above 30 percent, up from the 25 percent it estimated three months earlier, citing extremely robust artificial intelligence (AI)-related chip demand. “Our customers and customers’ customers, who are mainly cloud service providers, continue to send us very positive signals and outlook,” TSMC chairman and CEO C.C. Wei (魏哲家) said at an earnings conference. The company also hiked its capital expenditure for this year toward the higher end of its forecast, or US$56 billion, as it aims to step up advanced chip capacity expansions, such as
The founder of Chinese property giant Evergrande Group (恆大集團) has pleaded guilty to charges of fraud and bribery, a court said yesterday, the latest blow for what was once the country’s leading developer. Evergrande’s rise was propelled by decades of rapid urbanization and rising living standards, but in 2020, its access to credit dramatically narrowed when the government introduced curbs on excessive borrowing and speculation. The company defaulted in 2021 after struggling to repay creditors. Founder Xu Jiayin (許家印), 67, known as Hui Ka Yan in Cantonese, was reportedly held by police in 2023, with Evergrande saying he had been subjected to
RSS